poisar

Stocks · News reference

Precipio Q2 EPS $(0.12) Down From $0.05 YoY, Sales $7.021M Up From $5.654M YoY

Benzinga Newsdesk

Precipio (NASDAQ:PRPO) reported quarterly losses of $(0.12) per share. This is a 340 percent decrease over earnings of $0.05 per share from the same period last year. The company reported $7.021 million in sales this

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PRPO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

    Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.

    FLGTPRPO
  2. Benzinga Insights

    Precipio Q2 2026 Earnings Call: Complete Transcript

    Precipio (NASDAQ:PRPO) held its second-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and

    PRPO
  3. SEC EDGAR

    8-K filing — Precipio, Inc. (PRPO)

    Filed: 2026-08-14 AccNo: 0001104659-26-097364 Size: 227 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

    PRPO